Enlivex Therapeutics Ltd.

ENLV | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.81

+$0.08 (+11.39%)

At close: Sep 18, 2026, 4:00 PM ET

$0.88

+$0.07 (+8.07%)

Pre-market: Sep 21, 2026, 8:52 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+11.39%

(1D)

Rating

Updated: Sep 2, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $13.58M

1D Range

0.71 0.82

52W Range

0.64 27.15

Valuation (TTM)

PE 0

PB 0.01

EV/EBITDA -0.58

Valuation (NTM)

Forward PE N/A

Forward PEG -0.00

Price Target $15

Cash Flow

FCF Yield -81.7%

SBC Adj. FCF Yield -94.8%

SBC Impact -16.1%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 175.0% | 131.9%

FCF 3Y | 5Y 39.0% | 17.7%

Returns

ROA 53.1%

ROE 248.1%

ROIC -0.5%

Financial Health

Net Cash

$5.87M

Current Ratio 193.24

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is curre...

Sector Healthcare

Industry Biotechnology

Employees 34

IPO Date Jul 30, 2014

Website www.enlivex.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$15

Upside

+1751.85%

Buy (1)

Hold (1)

Sell (0)

Analyst Details ➞